^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lung Non-Small Cell Squamous Cancer

    Related cancers:
    2d
    A Complete Response to Immunotherapy in a Patient with Locally Advanced Squamous Cell Lung Cancer Harboring a Novel TMEM178B::BRAF Fusion: A Case Report. (PubMed, Diagnostics (Basel))
    The findings in this patient underscore the importance of extending molecular genetic studies to patients with squamous histology who lack toxic habits or known risk factors. Gene alterations such as BRAF rearrangements may not only predict the response to immunotherapy-based treatments but also represent a promising avenue for the development of new therapeutic strategies.
    Journal • IO biomarker
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF fusion • BRAF rearrangement
    2d
    Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial. (PubMed, Nat Med)
    Stage 1 results suggest that gotistobart monotherapy can provide clinically meaningful benefit for patients with programmed cell death protein/programmed death ligand 1-resistant and chemotherapy-resistant metastatic sqNSCLC. ClinicalTrials.gov identifier: NCT05671510 .
    P3 data • Journal
    |
    PD-L1 (Programmed death ligand 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    docetaxel • gotistobart (BNT316)
    2d
    A Retrospective Real-World Study Based on RATIONALE-307 (clinicaltrials.gov)
    P=N/A, N=109, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Active, not recruiting --> Recruiting
    Enrollment open • Real-world evidence
    |
    Tevimbra (tislelizumab-jsgr)
    4d
    A clinical study of V940 in people with non-small cell lung cancer (V940-013) (2025-520902-37-00)
    P1/2, N=15, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • carboplatin • docetaxel • albumin-bound paclitaxel • intismeran autogene (mRNA-4157)
    5d
    Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=12, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2025 --> May 2026
    Trial completion date
    |
    Keytruda (pembrolizumab) • carboplatin • gemcitabine • berzosertib (M6620)
    7d
    Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Pfizer
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    9d
    A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors (clinicaltrials.gov)
    P1/2, N=180, Recruiting, Alentis Therapeutics AG
    Trial initiation date
    11d
    Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=170, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    PD-L1 expression
    |
    tobemstomig (RG6139)
    12d
    A Retrospective Real-World Study Based on RATIONALE-307 (clinicaltrials.gov)
    P=N/A, N=109, Active, not recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New trial • Real-world evidence
    |
    Tevimbra (tislelizumab-jsgr)
    13d
    SYS6090 Combination Therapy in Advanced Lung Cancer (clinicaltrials.gov)
    P1/2, N=596, Not yet recruiting, Shanghai JMT-Bio Inc.
    New P1/2 trial
    |
    Avastin (bevacizumab) • paclitaxel • docetaxel • pemetrexed • etoposide IV • SYS6010
    13d
    Immune checkpoint inhibitor-related encephalitis overlapping with hyperprogression in metastatic lung cancer: a case report. (PubMed, Front Immunol)
    A 64-year-oldpatient with metastatic squamous NSCLC and high programmed death-ligand 1 (PD-L1) expression developed subacute neurological decline following pembrolizumab therapy, concurrent with rapid progression...This case underscores the need for vigilance toward the coexistence of rare neurotoxic irAEs and HPD during ICI therapy. Early recognition, multidisciplinary collaboration, and balanced therapeutic strategies are critical to optimizing outcomes.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • IL6 (Interleukin 6)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab)
    14d
    Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) (clinicaltrials.gov)
    P3, N=756, Active, not recruiting, Immutep S.A.S. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • pemetrexed • ImmuFact (eftilagimod alpha)